News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
700,100 Results
Type
Article (39737)
Company Profile (248)
Press Release (660115)
Multimedia
Podcasts (51)
Webinars (12)
Section
Business (204206)
Career Advice (2008)
Deals (35424)
Drug Delivery (95)
Drug Development (81053)
Employer Resources (172)
FDA (16189)
Job Trends (14865)
News (345254)
Policy (32548)
Tag
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (86)
Alliances (49453)
ALS (95)
Alzheimer's disease (1383)
Antibody-drug conjugate (ADC) (132)
Approvals (16187)
Artificial intelligence (264)
Autoimmune disease (22)
Automation (17)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (176)
Bladder cancer (79)
Brain cancer (27)
Breast cancer (292)
Cancer (2319)
Cardiovascular disease (179)
Career advice (1677)
Career pathing (30)
CAR-T (155)
Cell therapy (435)
Cervical cancer (20)
Clinical research (66092)
Collaboration (856)
Company closure (2)
Compensation (569)
Complete response letters (19)
COVID-19 (2590)
CRISPR (41)
C-suite (250)
Cystic fibrosis (102)
Data (2333)
Decentralized trials (2)
Denatured (19)
Depression (44)
Diabetes (275)
Diagnostics (6383)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (103)
Drug shortages (25)
Duchenne muscular dystrophy (96)
Earnings (87067)
Editorial (39)
Employer branding (21)
Employer resources (146)
Events (112688)
Executive appointments (741)
FDA (17569)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (770)
Gene editing (109)
Generative AI (20)
Gene therapy (314)
GLP-1 (719)
Government (4430)
Grass and pollen (4)
Guidances (161)
Healthcare (18823)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (125)
Indications (29)
Infectious disease (2735)
Inflammatory bowel disease (143)
Inflation Reduction Act (8)
Influenza (52)
Intellectual property (98)
Interviews (312)
IPO (16530)
IRA (40)
Job creations (3634)
Job search strategy (1422)
Kidney cancer (10)
Labor market (43)
Layoffs (475)
Leadership (17)
Legal (7910)
Liver cancer (76)
Lung cancer (325)
Lymphoma (157)
Machine learning (9)
Management (58)
Manufacturing (327)
MASH (77)
Medical device (13386)
Medtech (13391)
Mergers & acquisitions (19467)
Metabolic disorders (707)
Multiple sclerosis (83)
NASH (16)
Neurodegenerative disease (94)
Neuropsychiatric disorders (27)
Neuroscience (1941)
NextGen: Class of 2025 (6512)
Non-profit (4480)
Now hiring (40)
Obesity (371)
Opinion (205)
Ovarian cancer (81)
Pain (91)
Pancreatic cancer (88)
Parkinson's disease (154)
Partnered (22)
Patents (245)
Patient recruitment (116)
Peanut (46)
People (57354)
Pharmaceutical (63)
Pharmacy benefit managers (19)
Phase I (20593)
Phase II (29111)
Phase III (21676)
Pipeline (1381)
Policy (147)
Postmarket research (2563)
Preclinical (8760)
Press Release (64)
Prostate cancer (108)
Psychedelics (30)
Radiopharmaceuticals (247)
Rare diseases (384)
Real estate (5907)
Recruiting (65)
Regulatory (22330)
Reports (47)
Research institute (2321)
Resumes & cover letters (349)
Rett syndrome (6)
RNA editing (5)
RSV (42)
Schizophrenia (72)
Series A (131)
Series B (89)
Service/supplier (11)
Sickle cell disease (52)
Special edition (16)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3580)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (50)
The Weekly (30)
Vaccines (699)
Venture capitalists (42)
Weight loss (237)
Women's health (36)
Worklife (16)
Date
Today (191)
Last 7 days (979)
Last 30 days (3179)
Last 365 days (32579)
2025 (11913)
2024 (35220)
2023 (40076)
2022 (51173)
2021 (55717)
2020 (54092)
2019 (46545)
2018 (35025)
2017 (32115)
2016 (31484)
2015 (37556)
2014 (31319)
2013 (26346)
2012 (28575)
2011 (29266)
2010 (27334)
Location
Africa (718)
Alabama (54)
Alaska (7)
Arizona (233)
Arkansas (13)
Asia (37883)
Australia (6193)
California (6420)
Canada (2065)
China (539)
Colorado (274)
Connecticut (281)
Delaware (158)
Europe (81444)
Florida (957)
Georgia (215)
Idaho (57)
Illinois (567)
India (25)
Indiana (323)
Iowa (11)
Japan (172)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (922)
Massachusetts (4770)
Michigan (225)
Minnesota (404)
Mississippi (2)
Missouri (82)
Montana (27)
Nebraska (25)
Nevada (68)
New Hampshire (63)
New Jersey (1795)
New Mexico (28)
New York (1807)
North Carolina (989)
North Dakota (8)
Northern California (2835)
Ohio (210)
Oklahoma (14)
Oregon (34)
Pennsylvania (1429)
Puerto Rico (13)
Rhode Island (33)
South America (1097)
South Carolina (26)
South Dakota (1)
Southern California (2411)
Tennessee (106)
Texas (951)
United States (24062)
Utah (188)
Virginia (151)
Washington D.C. (64)
Washington State (566)
West Virginia (3)
Wisconsin (56)
700,100 Results for "ibio inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled “Low Glycemic Sugar Composition.”
Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative Laetose™ technology platform.
January 30, 2024
·
2 min read
iBio Accelerates Transformation to AI-Powered Biotech
BRYAN, Texas and SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) an AI-driven innovator of precision antibody immunotherapies, announces it is seeking to divest its contract development and manufacturing organization
November 10, 2022
·
7 min read
iBio to Participate in the H.C. Wainwright Global Investment Conference
BRYAN, Texas, May 18, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming® Manufacturing System,
November 10, 2022
·
1 min read
iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline
SAN DIEGO and BRYAN, Texas, Sept. 21, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System
November 10, 2022
·
7 min read
iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update
BRYAN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System,
November 10, 2022
·
15 min read
iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update
BRYAN, Texas and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the
November 10, 2022
·
10 min read
Business
RubrYc Therapeutics Announces Series A2 Preferred Equity Financing, Collaboration, and RTX-003 License with iBio, Inc.
RubrYc Therapeutics, Inc. (“RubrYc”) and iBio, Inc. (“iBio”, NYSEA: IBIO) announced today the closing of RubrYc’s Series A2 Preferred Financing, and concomitant License and Collaboration Agreements directed towards the research, development, and commercialization of epitope-targeted antibody therapeutics.
August 25, 2021
·
4 min read
Press Releases
CB Scientific, Inc. (CBSC) Announces Corporate Name Change to Cardiac Biotech Solutions, Inc.
May 8, 2025
·
4 min read
Press Releases
Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.
May 7, 2025
·
3 min read
Press Releases
Exagen Inc. Prices Public Offering of Common Stock
May 8, 2025
·
3 min read
1 of 70,010
Next
